Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study

Joanne R Morling; Jonathan A Fallowfield; Rachel M Williamson; Lisa D Nee; Andrew P Jackson; Stephen Glancy; Rebecca M Reynolds; Peter C Hayes; Indra N Guha; Mark W J Strachan; Jackie F Price

doi:10.1111/liv.12385

Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study

Joanne R Morling, Jonathan A Fallowfield, Rachel M Williamson, Lisa D Nee, Andrew P Jackson, Stephen Glancy, Rebecca M Reynolds, Peter C Hayes, Indra N Guha, Mark W J Strachan, Jackie F Price

Research output: Contribution to journal › Article › peer-review

Abstract

Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).

Original language	English
Pages (from-to)	1267-1277
Journal	Liver International
Volume	34
Issue number	8
Early online date	15 Nov 2013
DOIs	https://doi.org/10.1111/liv.12385
Publication status	Published - Sept 2014

Access to Document

10.1111/liv.12385

Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes
This is a PDF file of an unedited manuscript that has been accepted for publication. The final publisher version is available at: http://onlinelibrary.wiley.com/doi/10.1111/liv.12385/abstract
Accepted author manuscript, 814 KB

http://onlinelibrary.wiley.com/doi/10.1111/liv.12385/abstract

Clinical Training Fellowship for jo Morling: Progressive Fibrosis in Patients with Type 2 Diabetes Mellitus
Price, J.
UK-based charities
1/01/11 → 31/12/15
Project: Research
Inflammation, glucocorticoids abd microvascular disease in the aetiology of cognitive impairment in type 2 diabetes
Price, D.
MRC
1/06/06 → 30/11/11
Project: Research

Cite this

Morling, J. R., Fallowfield, J. A., Williamson, R. M., Nee, L. D., Jackson, A. P., Glancy, S., Reynolds, R. M., Hayes, P. C., Guha, I. N., Strachan, M. W. J., & Price, J. F. (2014). Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver International, 34(8), 1267-1277. https://doi.org/10.1111/liv.12385

@article{6b9c9726efc348ebb19bc5669c397ccb,

title = "Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study",

abstract = "Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).",

author = "Morling, {Joanne R} and Fallowfield, {Jonathan A} and Williamson, {Rachel M} and Nee, {Lisa D} and Jackson, {Andrew P} and Stephen Glancy and Reynolds, {Rebecca M} and Hayes, {Peter C} and Guha, {Indra N} and Strachan, {Mark W J} and Price, {Jackie F}",

note = "Funded by: UK Medical Research Council Diabetes UK Clinical Research Clinician Scientist Fellowship",

year = "2014",

month = sep,

doi = "10.1111/liv.12385",

language = "English",

volume = "34",

pages = "1267--1277",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley",

number = "8",

}

TY - JOUR

T1 - Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes

T2 - the Edinburgh type 2 diabetes study

AU - Morling, Joanne R

AU - Fallowfield, Jonathan A

AU - Williamson, Rachel M

AU - Nee, Lisa D

AU - Jackson, Andrew P

AU - Glancy, Stephen

AU - Reynolds, Rebecca M

AU - Hayes, Peter C

AU - Guha, Indra N

AU - Strachan, Mark W J

AU - Price, Jackie F

N1 - Funded by: UK Medical Research Council Diabetes UK Clinical Research Clinician Scientist Fellowship

PY - 2014/9

Y1 - 2014/9

N2 - Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).

AB - Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).

U2 - 10.1111/liv.12385

DO - 10.1111/liv.12385

M3 - Article

C2 - 24237940

SN - 1478-3223

VL - 34

SP - 1267

EP - 1277

JO - Liver International

JF - Liver International

IS - 8

ER -

Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study

Abstract

Access to Document

Fingerprint

Projects

Clinical Training Fellowship for jo Morling: Progressive Fibrosis in Patients with Type 2 Diabetes Mellitus

Inflammation, glucocorticoids abd microvascular disease in the aetiology of cognitive impairment in type 2 diabetes

Cite this